Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox

Published:2021-07-12 Issue:10 Volume:41 Page:968-980
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Yu Ke‐Da¹²^ORCID,Cai Yu‐Wen¹²,Wu Song‐Yang²,Shui Ruo‐Hong³,Shao Zhi‐Ming¹⁴

Affiliation:

1. Department of Breast Surgery Fudan University Shanghai Cancer Center Shanghai 200032 P. R. China

2. Shanghai Medical College Fudan University Shanghai 200032 P. R. China

3. Department of Pathology Fudan University Shanghai Cancer Center Shanghai 200032 P. R. China

4. Shanghai Key Laboratory of Breast Cancer Shanghai 200032 P. R. China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12191

Reference81 articles.

1. Re‐evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays;Regan MM;J Natl Cancer Inst,2006

2. The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast Cancer

3. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

4. Ki‐67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study

5. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reporting Hormone Receptor Expression in Breast Carcinomas: Which Method has the Highest Prognostic Power and What Should be the Optimal Cut-off Value?;International Journal of Surgical Pathology;2024-09-08

2. Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer;npj Precision Oncology;2024-09-05

3. MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas;Scientific Reports;2024-08-20

4. Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study;The Breast;2024-08

5. Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy;British Journal of Clinical Pharmacology;2024-07-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3